VX-770 IN SUBJECTS 6 TO 11 YEARS WITH CYSTIC FIBROSIS AND THE G551D-CFTR MUTATION

被引：0
|
作者：
Aherns, R. [1 ]
Rodriguez, S. [2 ]
Yen, K. [2 ]
Davies, J. C. [3 ]
机构：
[1] Univ Iowa, Iowa City, IA USA
[2] Vertex Pharmaceut Inc, Cambridge, MA USA
[3] Royal Brompton Hosp, London SW3 6LY, England
来源：
PEDIATRIC PULMONOLOGY | 2011年
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [31] Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis
    Elborn, Stuart
    Plant, Barry
    Konstan, Michael
    Aherns, Richard
    Rodriguez, Sally
    Munck, Anne
    Johnson, Charles
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [32] EFFECT OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS AND THE G551D-CFTR MUTATION WHO HAVE BASELINE FEV 1 > 90% OF PREDICTED
    Elborn, J. S.
    Rodriguez, S.
    Lubarsky, B.
    Gilmartin, G.
    Bell, S.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 298 - 298
  • [33] Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
    Rowe, Steven M.
    Liu, Bo
    Hill, Aubrey
    Hathorne, Heather
    Cohen, Morty
    Beamer, John R.
    Accurso, Frank J.
    Dong, Qunming
    Ordonez, Claudia L.
    Stone, Anne J.
    Olson, Eric R.
    Clancy, John P.
    PLOS ONE, 2013, 8 (07):
  • [34] Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation
    Elborn, J. Stuart
    Wainwright, Claire
    Sermet-Gaudelus, Isabelle
    Rodriguez, Sally
    Yen, Karl
    Ramsey, Bonnie
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [35] Effect of VX-770, a Cystic Fibrosis Transmembrane Conductance (CFTR) Potentiator, on Bone Phenotypes in ADO2 Mice
    Alam, Imranul
    Gerard-ORiley, Rita
    Acton, Dena
    Hong, Jung Min
    Bruzzaniti, Angela
    Econs, Michael J.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 265 - 265
  • [36] Mechanism of G551D-CFTR (cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog
    Bompadre, Silvia G.
    Li, Min
    Hwang, Tzyh-Chang
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (09) : 5364 - 5369
  • [37] Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
    Quittner, Alexandra
    Suthoff, Ellison
    Rendas-Baum, Regina
    Bayliss, Martha S.
    Sermet-Gaudelus, Isabelle
    Castiglione, Brenda
    Vera-Llonch, Montserrat
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
  • [38] Long-term safety and efficacy of ivacaftor in subjects with CF who have the G551D-CFTR mutation
    McKone, Edward
    Rodriguez, Sally
    Yen, Karl
    Davies, Jane
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [39] Effect of VX-770 (Ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells
    Vachel, Laura
    Norez, Caroline
    Becq, Frederic
    Vandebrouck, Clarisse
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (06) : 584 - 591
  • [40] Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
    Alexandra Quittner
    Ellison Suthoff
    Regina Rendas-Baum
    Martha S. Bayliss
    Isabelle Sermet-Gaudelus
    Brenda Castiglione
    Montserrat Vera-Llonch
    Health and Quality of Life Outcomes, 13
12345